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Abstract 
Purpose: To describe lipoatrophy of the plantar pedis fat pads in HIV patients with or without 
long-term antiretroviral therapy (ART); to compare the characteristics of ART patients with 
and without plantar pedis lipoatrophy; and to examine the effects of HIV and 
metabolic/cardiovascular risk parameters and treatment history on plantar pedis lipoatrophy.  
Design: One hundred and thirty four patients who started PI-ART in 1996 and 49 
treatment naïve patients, recruited 2004, were examined and graded for lipoatrophy of five 
body compartments including the plantar fat pads eight years after start of ART. Baseline 
HIV- and ART-related factors were documented together with follow up 
metabolic/cardiovascular risk parameters.  
Results: Plantar pedis lipoatrophy occurred more often among ART patients (60%) than 
among treatment naïve patients (12%; p <0.001). ART patients with plantar lipoatrophy were 
older, had higher PAI-1 values, a higher prevalence of lipoatrophy in other body 
compartments, and longer stavudine and didanosine treatment history as compared to patients 
without plantar lipoatrophy. In multiple logistic regression, the best predictive model for 
plantar lipoatrophy was increased PAI-1 when HIV and metabolic/cardiovascular risk 
parameters were studied and treatment with didanosine when treatment history was studied. 
Increased PAI-1 was not associated to lioatrophy in any other location. 
Conclusions: Plantar lipoatrophy is common among patients on long-term ART and, 
although often overlooked, may cause significant discomfort. The association to PAI-1, a well 
known marker of increased cardiovascular risk, is intriguing and further focuses on the need 
of an active approach to evaluating and lowering cardiovascular risk factors in long-term HIV 
treatment.  
Keywords: Adverse effects, antiviral therapy, body changes, metabolic disorders, 
plasminogen activator inhibitor 1 
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Introduction 
Since the introduction of protease inhibitors (PI) in antiretroviral therapy (ART) in 1996, the 
mortality and incidence of AIDS-related conditions has declined dramatically (Mocroft et al., 
2003). However, ART is itself associated with metabolic abnormalities including 
hyperlipidemia, insulin resistance, and subcutaneous and visceral liopdystrophy. The degree 
of lipodystrophy (loss of subcutaneous fat and the accumulation of visceral fat) is in daily 
clinical life generally assessed on the basis of subjective observation by the patient and or 
clinician. ART-associated lipodystrophy has been reported in 11 to 83% of patients receiving 
ART (Carter et al., 2001; Grinspoon & Carr, 2005; Hansen et al., 2006; Mauss et al., 2002) 
and several studies suggests that lipodystrophy is associated with negatively affected health-
related quality of life (Guaraldi et al., 2008; Nicholas, Kirksey, Corless, & Kemppainen, 
2005) and or adherence to therapy (Guaraldi et al., 2008). There is increasing evidence that 
the subcutaneous lipoatrophy may develop from an independent mechanism to the often co-
existing absolute or relative abdominal lipohypertrophy, often combined with increased fat in 
the liver (Grinspoon & Carr, 2005; Saint-Marc et al., 1999). Peripheral lipoatrophy has been 
correlated to older age, advanced disease stage, longer duration of ART, and the nucleoside 
analogue reverse transcriptase inhibitors (NRTI) stavudine, didanosine, and zidovudine (Carr 
et al., 1998; Lichtenstein, 2005; Mallon, Miller, Cooper, & Carr, 2003; Mauss et al., 2002; 
Miller et al., 2003; G. J. Moyle, 2005; Saint-Marc et al., 1999) while central lipohypertrophy 
has been correlated with older age and treatment with stavudine and in particular PIs (Heath et 
al., 2002; Lichtenstein, 2005; Miller et al., 2003; G. Moyle, 2007). The pathogenic 
mechanisms suggested for lipoatrophy include deranged fat cell differentiation or apoptosis 
and mitochondrial toxicity (Lichtenstein, 2005). Stavudine, didanosine, and, to some extent, 
zidovudine interfere with mitochondrial gamma polymerase (Villarroya, Domingo, & Giralt, 
2005). Fat biopsies from patients on NRTI-containing ART have been shown to have lower 
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mitochondrial DNA content and RNA expression (Mallon et al., 2008). PIs with the exception 
of atazanavir inhibit lipogenesis and adipocyte development, increase lipolysis and induce 
insulin resistance directly through the inhibition of glucose transport into the cell and 
indirectly through abdominal obesity (Grinspoon & Carr, 2005; G. Moyle, 2007; Murata, 
Hruz, & Mueckler, 2002; Noor, Flint, Maa, & Parker, 2006). Also NRTIs have been found to 
decrease insulin sensitivity, possibly due to increased lipolysis (Blumer et al., 2008). 
Plasminogen activator inhibitor type 1 (PAI-1) is an important inhibitor of fibrinolysis, 
contributes to the pathogenesis of atherosclerosis and is a well known risk factor for coronary 
artery disease (Kohler & Grant, 2000). Increased PAI-1 has been reported in lipodystrophy 
(He et al., 2005), seems to be linked to the insulin resistance (De Larranaga, Galich, Puga, 
Alonso, & Benetucci, 2004), and is possibly produced, together with other cardiovascular risk 
factors, in the fatty liver (Yki-Jarvinen, 2005). In our clinical practice, we have made a new 
observation in patients on ART reporting non-neuropathic foot pain while walking and 
standing. Some of these patients display a pronounced reduction of the plantar pedis fat pads. 
However, apart from case reports (Stupar & Tibbles, 2008), no systematic studies have been 
published investigating the prevalence of plantar lipoatrophy and its contributing factors.  
The purposes of this study were: 1) to describe and compare the prevalence of 
lipoatrophy of the plantar pedis fat pads in long term ART patients and ART naïve patients, 2) 
to describe and compare the characteristics of HIV-infected patients with and without 
lipoatrophy of the plantar pedis fat pads, and 3) to examine the influence of baseline clinical 
characteristics, current metabolic and cardiovascular risk parameters, and treatment history on 
lipoatrophy of the plantar pedis fat pads in ART patients. 
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Materials and Methods 
Patients 
Treatment with PIs in the form of indinavir TID or ritonavir BID was introduced at Venhälsan 
HIV clinic, Stockholm South General Hospital, Stockholm in 1996. All 202 patients who 
started PI-ART in 1996 were included in a clinical cohort to be monitored prospectively. 
During year 2004 the remaining 160 patients from this cohort (30 patients had died and 12 
had moved to another city or country; ART patients) were, together with an additional 89 
consecutive treatment naïve HIV-positive patients (ART naïve control group) visiting the 
clinic for their routine checkup, invited to participate in the present study. All potential 
participants received oral and written information about the present study by their responsible 
staff nurse. Those who agreed to participate were asked to sign a consent form. The patients 
were invited to give blood samples for the analyses specified below and to have a physical 
examination of potential lipoatrophy by a plastic surgeon not involved in the care of the 
patients. The study procedures and research instruments were reviewed and approved by an 
institutional ethics committee (South Review Board of Research Ethics, Huddinge University 
Hospital).  
 
Measurements 
Lipoatrophy 
The plastic surgeon performed a systematic physical examination with "fat mapping" 
including an "in house" standardized grading of the degree of subcutaneous fat wasting in the 
following regions: face, gluteal regions, thigh, palm, and sole of the foot. The degree of 
regional lipoatrophy was rated on a 0–5 scale. In addition, the body mass index (BMI) and 
waist–hip ratio (WHR) were calculated. 
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Baseline clinical characteristics  
For the ART subsample of patients, data at baseline (i e at PI-ART start, year 1996) on age, 
time since HIV diagnosis, AIDS diagnosis, NRTI experience at the start of PI, HIV-RNA 
(Roche ultra-sensitive test, version 1.5; frozen samples), and CD4 cell count (lyse-no-wash 
preparation and "single-platform" procedure with reagents from Becton Dickinson, Hägersten, 
Sweden) were obtained by reviewing the patients’ medical records. Furthermore, the history 
of ART with the exact treatment time in days on each individual drug was calculated.  
 
Current CD4, metabolic and other cardiovascular risk parameters  
All blood was sampled during morning hours with the patients fasting since midnight. CD4 
cell measurements were performed by the Swedish Institute for Infectious Disease Control 
(lyse-no-wash preparation and "single-platform" procedure with reagents from Becton 
Dickinson, Hägersten, Sweden). All other laboratory tests were performed by the Laboratory 
of Clinical Chemistry at Huddinge University Hospital (accreditation by the Swedish Board 
for Accreditation and Conformity Assessment) with standard biochemical methods where not 
otherwise indicated.  
The fasting plasma levels of glucose and insulin were determined. The homeostatic 
model assessment for insulin resistance (HOMA-IR) was calculated using the formula 
[HOMA-IR = (insulin (pmol/l) / 6.945 × glucose (mmol/l)) / 22.5]. A HOMA-IR index above 
3 indicates insulin resistance. Triglycerides (TG), total cholesterol (TC), high density 
lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo A1), apolipoprotein B (Apo B), and 
lipoprotein (a) (Lp(a)) were determined. Low density lipoprotein cholesterol (LDL-C) was 
calculated using the Friedewald formula. High sensitivity C-reactive protein (hsCRP) was 
determined. The plasma level of PAI-1 was determined on citrated plasma with the 
Chromolize PAI-1 kit (Biopool AB, Umeå, Sweden).  
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Statistical methods 
Statistical analyses were performed with SPSS for windows version 13.0. The criterion for 
accepting statistical significance was p <0.05. The non-parametric Mann Whitney U-test was 
used for pair wise group comparisons of continuous and scaled variables. Fisher’s exact test 
was used for group comparisons on frequency data. Logistic regression analyses were 
performed to study the influence of different potentially related variables on the odds ratio 
(OR) for development of lipoatrophy of the plantar fat pads among the patients up to eight 
years after start of PI-ART (follow up). First, the influence of each independent variable on 
the dependent variable was analysed univariately. Subsequently, those independent variables 
statistically significant in the univariate analysis were entered simultaneously in a multiple 
logistic regression. The independent variables investigated were a set of potential risk 
variables at baseline and the outcome of the different relevant metabolic and cardiovascular 
risk parameters at follow up. In a second set of analyses, the influence on treatment with 
didanosine and stavudine on the OR for development of lipoatrophy of the plantar fat pats 
was performed. The independent variables were dichotomised as follows: age was coded into 
the lowest quartile (i e the youngest patients) versus the other three quartiles; HIV-RNA at 
baseline was coded by less than 100,000 copies/ml versus equal or above 100,000 copies/ml; 
CD4 count and time with known HIV infection at baseline were coded as below or equal 
versus above the group median values; the metabolic and cardiovascular risk parameters at 
follow up were coded regarding to the laboratory’s reference values (i e normal versus 
pathological); the follow up Lp(a) was coded as above or below 300 mg/l; the follow up 
HOMA-IR index was coded as below or above 3. Treatment with didanosine and stavudine 
were coded as ever treated or never treated with the respective drug. At last, to study the 
association between abnormal PAI-1 and lipoatrophy of all investigated body regions, a 
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multiple logistic regression analysis was performed with PAI-1 as the dependent variable and 
lipoatrophy in face, gluteal regions, thigh, palm, and sole of the foot as the independent 
variables.
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Results 
Study participation 
The majority of both ART patients and the ART naïve control patients agreed to take part in 
the study (134/160 (84%) ART patients: 125 men who hav sex with men (MSM), 7 women, 
and 2 heterosexual men; 49/89 (55%) ART naïve patients: 48 MSM and 1 heterosexual man).  
 
Representability of the participants 
Comparisons between participants and non-participants within the ART patients (n=134 and 
26, respectively) and within the ART naïve control group (n=49 and 40, respectively), 
regarding age, AIDS, CD4, HIV-RNA, and months since HIV diagnosis did not show any 
statistically significant difference (data not shown).  
 
Baseline characteristics of the ART patients 
At PI-ART start (year 1996; baseline; n=134) the median age was 39.5 (inter quartile range 
(IQR) 34–45, mean 40, standard deviation (SD) 8) years, the median CD4 count 210 (IQR 
80–320) × 106 cells/l, the median RNA level 61,100 (IQR 9,725–192,825) copies/ml, and the 
median time with known HIV infection 87.5 (IQR 42–125) months. Forty-seven percent had a 
CD4 count below 200 × 106 cells/l, 30% had been diagnosed with AIDS, and 55% had either 
a CD4 count below 200 × 106 cells/l or AIDS. A majority of the ART patients, 93/134 (69%), 
were NRTI experienced, usually to zidovudine and or didanosine, when starting PI-ART 
(118/134 (88%) started with indinavir and 16/134 (12%) with ritonavir). The patients have 
been treated according to best clinical practice by their individual healthcare team. Most of 
the patients have changed treatment several times due to viral failure, side effects, or a wish to 
simplify the regimen. At follow-up (year 2004) the median time since the start of PI-ART was 
7.8 years (range 7.1–8.3 years). 
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Comparisons of demographic, clinically and metabolic characteristics  
Comparisons regarding the ART patients' and the ART naïve control patients' demographic, 
clinically and metabolic characteristics at follow-up are shown in Table 1. Not surprisingly, 
the ART patients were older and had longer known time with HIV infection as compared to 
the ART naïve patients. The ART patients had lower weight and BMI and higher WHR than 
the ART naïve patients. When comparing the metabolic and cardiovascular risk laboratory 
parameters, the ART patients had higher values of the "bad" lipid levels TG, TC, LDL-C and 
Apo B, but also of the "good" lipids HDL-C and Apo A1. Furthermore, HOMA-IR was 
higher among the ART patients, suggesting a higher degree of insulin resistance among the 
patients on treatment.  
 
Prevalence of lipoatrophy of the plantar pedis fat pads 
Lipoatrophy of the plantar pedis fat pads was found in 81/134 (60%) of the ART patients as 
compared to 6/49 (12%) of the ART naïve control patients (p <0.001). Three of the six ART 
naïve patients with plantar pedis lipoatrophy had HOMA above 3 indicating insulin 
resistance.  
 
Prevalence of lipoatrophy in other locations than the plantar pedis  
Lipoatrophy of the hand was found in 44/134 (33%) of the ART patients and 4/49 (8%) of the 
ART naïve control patients (p <0.001), gluteal lipoatrophy was found in 68/134 (51%) of the 
treated and none of the naïve patients (p <0.001), thigh lipoatrophy was found in 69/134 
(51%) of the treated and 3/49 (6%) of the naïve patients (p <0.001), and face lipoatrophy was 
found in 48/134 (36%) of the treated and 1/49 (2%) of the naïve patients (p <0.001). 
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Comparison between the ART patients with and without plantar pedis 
lipoatrophy 
Comparisons between the ART patients with and without plantar pedis lipoatrophy are shown 
in Table 2. The patients with plantar lipoatrophy were older and had higher PAI-1 values 
indicating a more atherogenic profile as compared to the patients without plantar lipoatrophy. 
When comparing treatment time on different individual drugs, the patients with plantar 
lipoatrophy had been longer on didanosine and stavudine as compared to the patients without 
plantar lipoatrophy. Not surprisingly, the patients with plantar lipoatrophy also had a higher 
prevalence of lipoatrophy of the other investigated body compartments as compared to the 
patients without plantar lipoatrophy. 
 
Effects of baseline clinical characteristics and current parameters on 
plantar pedis lipoatrophy among ART patients 
The results of the univariate logistic regression analyses to investigate the effects of baseline 
clinical characteristics and current metabolic and cardiovascular risk parameters on plantar 
pedis lipoatrophy are shown in Table 3. Only baseline CD4 count below median and currently 
abnormal PAI-1 (i e, above 15kIE/l) were statistically significant associated with lipoatrophy 
of the plantar pedis fat pads. The OR for having plantar pedis lipoatrophy was 2.13 for those 
having a baseline CD4 count below median as compared to those having a baseline CD4 
count above median. Further, the OR for having plantar pedis lipoatrophy was 2.69 for those 
having abnormal PAI-1 as compared to those having PAI-1 within the normal range (i e, 
below 15kIE/l). There was no statistically significant association to NRTI experience at PI-
ART start, disease stage, age, HIV-RNA, months with HIV infection, lipid values, HOMA-IR 
or hsCRP.  
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In the multivariate logistic regression analysis, when baseline CD4 count and current 
PAI-1 were entered simultaneously into the equation, only PAI-1 showed a statistically 
significant association to plantar pedis lipoatrophy. When the effects of baseline CD4 count 
was adjusted for, the OR for having plantar pedis lipoatrophy was 2.52 for those having 
abnormal PAI-1 as compared to those having PAI-1 within the normal range. 
 
Effects of treatment history with different antiretroviral drugs on 
plantar pedis lipoatrophy among ART patients 
When the effects of treatment with didanosine and stavudine were investigated in univariate 
logistic regression analyses, treatment history with didanosine showed a statistically 
significant association with plantar pedis lipoatrophy. The OR for having plantar pedis 
lipoatrophy was 3.12 for those having a treatment history with didanosine as compared to 
those without a treatment history with didanosine (Table 3).  
 
The effects of lipoatrophy at various locations on increased PAI-1 
among ART patients 
As abnormal PAI-1 was the strongest predictor of plantar pedis lipoatrophy and there was a 
relation between plantar pedis lipoatrophy and lipoatrophy in the other investigated body 
regions, a multivariate logistic regression analysis was performed to investigate the effect of 
lipoatrophy of all investigated body regions on the OR for having an abnormal PAI-1. The 
result showed that only plantar pedis lipoatrophy had a statistically significant effect on the 
OR for having abnormal PAI-1. The OR for having abnormal PAI-1 was 2.92 for those 
having plantar pedis lipoatrophy as compared to those not having plantar pedis lipoatrophy 
when the effects of lipoatrophy at the other investigated locations were adjusted for (Table 4).  
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Discussion 
This cross-sectional study revealed that the vast majority of the HIV-infected patients on long 
term ART had a reduction of the plantar pedis fat pads. HIV-associated lipoatrophy of this 
particular region has, to our knowledge, not been systematically described before. 
Furthermore, the study also revealed a high prevalence of lipoatrophy in other body regions.  
The patients with plantar lipoatrophy were characterised by higher age, higher PAI-1, 
higher prevalence of lipoatrophy in other regions, and longer didanosine and stavudine 
exposure. In the multivariate logistic regression analysis including HIV and metabolic 
parameters, the best predictive model for plantar pedis lipoatrophy was increased PAI-1. 
Although thinning of the plantar fat pads has been described in non-HIV-infected diabetic 
patients with polyneuropathy (Bus, Maas, Cavanagh, Michels, & Levi, 2004), we did not find 
any association to insulin resistance among the ART patients. However, plantar pedis 
lipoatrophy was also found in 12% of the ART naïve patients, half of whom had signs of 
insulin resistance.  
Autopsy studies have shown the fat pads of the feet to have a significant nerve and 
blood supply separate from the surrounding musculature and a meshwork of septa arranged in 
closed-cell configuration, creating a delicate weight bearing structure (Jahss et al., 1992). It is 
likely that the fat hypotrophy found in this study impairs this cushioning function. The 
consequences for the patient might be pain and stiffness while standing and walking.  
HIV infection, both before and after the introduction of PI-ART, is associated with a 
pro-atherogenic lipid profile characterized by an increase in triglyceride levels, a decrease in 
HDL-C, and the presence of small LDL-C particles (Riddler et al., 2003; Salyer, Lyon, Settle, 
Elswick, & Rackley, 2006). Patients on ART for six years had decreased HDL-C and BMI 
and increased TG and insulin values as compared to HIV-negative healthy controls (Hansen 
et al., 2006). In the present study, we found that the ART patients had higher triglycerides, 
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LDL-C, and HOMA-IR indices and lower BMI as compared to the ART naïve HIV-positive 
controls. However, we found the HDL-C and ApoA1 levels to be higher among the ART 
patients, possibly reflecting treatment induced reversion of HIV-induced lipid abnormalities.  
PAI-1, but not triglycerides, hsCRP, or HOMA was associated with plantar pedis 
lipoatrophy. No association of increased PAI-1 was found to lipoatrophy in any other 
location. Abdominal and liver fat is an important source of PAI-1 (Alessi et al., 1997; Yki-
Jarvinen, 2005). PAI-1 is increased in patients with abdominal obesity and insulin resistance 
(Alessi et al., 1997; Kohler & Grant, 2000) and among ART patients with lipodystrophy 
(Hadigan et al., 2001; He et al., 2005). We have previously found increased PAI-1 values to 
be associated to PI-ART (Koppel, Bratt, Schulman, Bylund, & Sandstrom, 2002). Visceral 
adiposity and insulin resistance is reported to be the main predictor of plasma PAI-1 levels in 
patients with lipodystrophy (De Larranaga et al., 2004; He et al., 2005). PAI-1, overproduced 
by the fatty liver is linked to dysregulation of the TNF- system (He et al., 2005). Increased 
TNF- expression in lipoatrophic tissue has been suggested as a possible cause of impaired 
adipocyte development and apoptosis (Bastard et al., 2002). Thus, PAI-1 might be of 
importance for the development of plantar pedis lipoatrophy through facilitation of 
thrombotic micro events and increasing the clots resistance to fibrinolysis in the small 
interseptal vessels.  
Certain study limitations should be emphasised when interpreting the results. Firstly, the 
great majority of the investigated cohort was male patients who started PI-ART in an 
advanced stage of HIV infection and had prior experience of NRTI mono- or dual therapy. 
The inferences drawn from this study might not be applicable to women nor to ART naïve 
patients starting antiretroviral therapy today in a less advanced stage of the disease and with 
more metabolically tolerable combinations. With regard to gender, however, a recent study 
has shown that lipodystrophy is at least as common if not even more so (including fat loss 
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from lower limbs) in women (Galli et al., 2003), indicating that the present study findings 
may well be of importance for both sexes. Secondly, as expected, the treatment naïve control 
group was younger and had had shorter known time with HIV infection as compared to the 
ART patients. On the other hand, it is our opinion that a comparison with a HIV-positive 
control group has an advantage in sorting out more specific ART related effects in contrast to 
using a matched HIV-negative control group. Thirdly, there were some problems motivating 
the naïve controls to participate in the study. However, there were no apparent demographic 
or clinical differences between the participating and non-participating control patients.  
 
Conclusion 
In conclusion, evaluation of the plantar pedis fat pads in patients on ART should be 
performed regularly by the responsible physician or nurse specialist, especially when there are 
signs of lipoatrophy in other areas and regardless of any spontaneously reported leg or foot 
discomfort. Because of the proposed relation to increased cardiovascular risk, the presence of 
plantar lipoatrophy and or foot pain might also indicate the need of cardiovascular risk 
reduction interventions. Furthermore, the presence of plantar pedis lipoatrophy should 
actualize the need to reconsider the patient's ART regimen with the goal to avoid zidovudine, 
didanosine and stavudine whenever possible. Further research about the causes of plantar 
pedis lipoatrophy is needed to prevent and relieve the patients suffering. The strong 
association with PAI-1 suggests possible treatment options with anticoagulants and or drugs 
that decrease liver and central fat accumulation.  
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Table 1. Comparison between the participating ART and ART-naïve control patients; all values 
originate from the time point where the systematic physical examination with "fat mapping" was 
performed 
Variable ART patients  
(n=134) 
ART-naïve 
patients (n=49) 
 
 
 median (IQR)/ 
frequency (%) 
Median (IQR)/ 
Frequency (%) 
p 
Age (years) 48 (42–53) 40 (36–45) <0.001a 
Time with HIV (months) 172 (126–209) 50 (25–123) <0.001a 
CD4 (×106cells/l) 524 (330–656) 445 (353–635) 0.725a 
Weight (kg) 72 (65–78) 75 (71–86) 0.002a 
BMI 22.5 (20.6–24.0) 23.8 (22.1–26.4) 0.003a 
WHR 0.95 (0.91–0.98) 0.90 (0.87–0.97) 0.001b 
TG (mmol/l) 1.9 (1.1–2.9) 1.2 (0.8–1.9) <0.001a 
TC (mmol/l) 5.4 (4.6–6.2) 4.2 (3.7–5.0) <0.001a 
HDL-C (mmol/l) 1.3 (1.1–1.6) 1.1 (0.9–1.4) 0.007a 
LDL-C (mmol/l) 3.1 (2.4–3.8) 2.5 (2.2–3.0) 0.003a 
Lp(a) (mg/l) 163 (91–507) 140 (61–362) 0.316a 
PAI-1 (kIE/l) 13.5 (8.0–29.3) 9.0 (4.3–16.0) 0.008a 
Apo A1 (mmol/l) 1.3 (1.2–1.5) 1.1 (1.0–1.2) <0.001a 
Apo B (mmol/l) 1.0 (0.8–1.2) 0.8 (0.7–0.9) <0.001a 
hsCRP (mg/l) 1.7 (0.8–4.0) 1.3 (0.7–2.7) 0.056a 
HOMA-IR 2.0 (1.3-3.1) 1.4 (0.8-2.8) 0.009a 
aMann Whitney U-test; Apo A1apo A1 lipoprotein; Apo Bapo B lipoprotein; ARTantiretroviral 
therapy; BMIbody mass index; HOMA-IRhomeostatic model assessment for insulin resistance; 
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hsCRPhigh sensitivity C-reactive protein; HDL-Chigh density lipoprotein cholesterol; IQRinter 
quartile range; LDL-Clow density lipoprotein cholesterol; Lplipoprotein; PAIplasminogen 
activator inhibitor; TCtotal cholesterol; TGtriglycerides; WHRwaist hip ratio 
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Table 2. Comparison between the ART patients with and without plantar pedis lipoatrophy 
Variable ART patients with 
plantar pedis 
lipoatrophy 
(n=81) 
ART patients 
without plantar 
pedis lipoatrophy 
(n=53) 
 
 
 
 
 median (IQR)/ 
frequency (%) 
Median (IQR)/ 
Frequency (%) 
p 
Age at PI-ART start (years) 40 (35–46) 38 (32–44) 0.025a 
Time with HIV at PI-ART start (months) 88 (48–121) 87 (34–128) 0.913a 
HIV-RNA at PI-ART start (log10 
copies/ml) 
4.8  (4.1–5.4) 4.6 (3.9–5.1) 0.174a 
CD4 at PI-ART start (×106cells/l) 160 (61–290) 230 (115–340) 0.077a 
CD4 <200 ×106cells/l or AIDS at PI-
ART start (freq) 
49/81 (61%) 24/53 (45%) 0.11b 
Actual CD4 (×106cells/l) 485 (323–627) 557 (351–689) 0.211a 
TG (mmol/l) 1.9 (1.2–3.3) 1.9 (1.0–2.7) 0.177a 
TC (mmol/l) 5.3 (4.6–6.2) 5.4 (4.5–6.1) 0.935a 
HDL-C (mmol/l) 1.2 (1.1–1.5) 1.3 (1.1–1.6) 0.312a 
LDL-C (mmol/l) 3.1 (2.4–3.8) 3.2 (2.4–3.8) 0.654a 
HOMA-IR 2.2 (1.3–3.4) 1.7 (1.1–2.7) 0.180a 
Lp(a) (mg/l) 178 (105–535) 139 (50–427) 0.240a 
PAI-1 (kIE/l) 17.0 (9.0–31.5) 11.0 (6.0–25.5) 0.039a 
Apo A1 (mmol/l) 1.31 (1.15–1.51) 1.36 (1.21–1.57) 0.423a 
Apo B (mmol/l) 1.00 (0.82–1.20) 1.07 (0.83–1.18) 0.943a 
hsCRP (mg/l) 1.8 (1.1–6.0) 1.3 (0.7–3.4) 0.052a 
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Weight (kg) 71.4 (63.9–77.3) 72.9 (65.2–79.0) 0.568a 
BMI 22.1 (20.5–23.7) 22.8 (21.3–24.4) 0.280a 
WHR 0.95 (0.92–0.99) 0.94 (0.90–0.97) 0.078a 
Exposure to zidovudine (months) 71 (47–92) 78 (44–95) 0.825a 
Exposure to lamivudine (months) 81 (63–90) 79 (60–90) 0.667a 
Exposure to didanosine (months) 28 (3–66) 5 (0–32) 0.002a 
Exposure to stavudine (months) 30 (0–53) 12 (0–43) 0.042a 
Lipoatrophy of the face (freq) 37/81 (46%)   11/53 (21%) 0.003b  
Lipoatrophy of the palms (freq) 36/81 (44%)  8/53  (15%) <0.001b 
Lipoatrophy of the thigh (freq) 49/81 (60%)  20/53 (38%) 0.013b  
Lipoatrophy of the gluteal region (freq) 49/81 (60%)  19/53 (36%) 0.008b  
aMann Whitney U-test; bFisher’s exact test; Apo A1apo A1 lipoprotein; Apo Bapo B lipoprotein; 
ARTantiretroviral therapy; BMIbody mass index; freqfrequency; hsCRPhigh sensitivity C-reactive 
protein; HDL-Chigh density lipoprotein cholesterol; HOMA-IRhomeostatic model assessment for 
insulin resistance;  IQRinter quartile range; LDL-Clow density lipoprotein cholesterol; 
Lplipoprotein; PAIplasminogen activator inhibitor; PIprotease inhibitor; SHBGsex hormone 
binding globulin; TCtotal cholesterol; TGtriglycerides; WHRwaist hip ratio 
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Table 3. Logistic regressions; OR for plantar pedis lipoatrophy related to different baseline clinical 
characteristics, current metabolic and cardiovascular risk parameters, and treatment history among the ART 
patients. Plantar pedis lipoatrophy was regarded as the dependent variable. The independent factors that 
showed statistically significant ORs in the univariate logistic regressions related to baseline and 
metabolic/cardiovascular risk parameters were entered simultaneously in the multiple logistic regression 
 Univariate logistic regression Multiple logistic regression 
 OR CI 95% P OR CI 95% p 
Baseline clinical characteristics       
NRTI experience at PI-ART start: 
    Naïve  
    NRTI experienced  
 
Reference 
1.73 
 
 
0.82–3.65 
 
 
0.149 
   
Clinical stage: 
    CD4 >200 and no AIDS  
    AIDS or CD4 <200  
 
Reference 
1.85 
 
 
0.92–3.73 
 
 
0.085 
   
Age: 
    Age <34 years  
    Age >34 years  
 
Reference 
2.12 
 
 
0.99–4.56 
 
 
0.054 
   
HIV-RNA: 
    <100,000 copies/ml  
    >100,000 copies/ml  
 
Reference 
2.02 
 
 
0.96–4.25 
 
 
0.064 
   
CD4: 
    >median  
    <median  
 
Reference 
2.13 
 
 
1.05–4.34 
 
 
0.038 
 
 
1.95 
 
 
0.94–4.04 
 
 
0.074 
Months with known HIV infection: 
    <median  
 
Reference 
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    >median  1.05 0.52–2.07 0.918 
Current metabolic/cardiovascular 
risk parameter  
      
TG: 
    <1.7 mmol/l  
    >1.7 mmol/l  
 
Reference 
0.91 
 
 
0.45–1.83 
 
 
0.795 
   
TC: 
    <6.5 mmol/l  
    >6.5 mmol/l  
 
Reference 
0.85 
 
 
0.33–2.18 
 
 
0.736 
   
HDL-C: 
    >0.9 mmol/l 
    <0.9 mmol/l 
 
Reference 
0.82 
 
 
0.33–2.04 
 
 
0.673 
   
HOMA-IR: 
    <3.0  
    >3.0  
 
Reference 
1.51 
 
 
0.67–3.44 
 
 
0.322 
   
Lp (a): 
    <300 mg/l  
    >300 mg/l  
 
Reference 
1.12 
 
 
0.54–2.34 
 
 
0.765 
   
PAI-1 
    <15 kIE/l  
    >15 kIE/l  
 
Reference 
2.69 
 
 
1.31–5.52 
 
 
0.007 
 
 
2.52 
 
 
1.22–5.23 
 
 
0.013 
Apo A1: 
    >1.1 mmol/l  
    <1.1 mmol/l  
 
Reference 
0.86 
 
 
0.34–2.22 
 
 
0.759 
   
Apo B:       
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    <1.5 mmol/l  
    >1.5 mmol/l  
Reference 
1.11 
 
0.25–4.86 
 
0.889 
hsCRP: 
    <1.8 mg/l 
    >1.8 mg/l 
 
Reference 
1.34 
 
 
0.67–2.68 
 
 
0.414 
   
Treatment history       
Ever treated with didanosine: 
    No 
    Yes 
 
Reference 
3.12 
 
 
1.44–6.73 
 
 
0.004 
 
 
NA 
  
Ever treated with stavudine: 
    No 
    Yes 
 
Reference 
1.39 
 
 
0.68–2.86 
 
 
0.373 
   
Apo A1apo A1 lipoprotein; Apo Bapo B lipoprotein; ARTantiretroviral therapy; CIconfidence interval; HDL-
Chigh density lipoprotein cholesterol; HOMA-IRhomeostatic model assessment for insulin resistance; 
hsCRPhigh sensitivity C-reactive protein; NAnot applicable; NRTInucleoside analogue reverse transcriptase 
inhibitor; Lplipoprotein; ORodds ratio; PAIplasminogen activator inhibitor; PIprotease inhibitor; TCtotal 
cholesterol; TGtriglycerides 
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Table 4. Logistic regressions; OR for abnormal PAI-1 (>15 kIE/l) related to 
lipoatrophy at different locations when entered simultaneously into a multiple 
logistic regression 
 
Multiple logistic regression 
 OR CI 95% p 
Lipoatrophy location    
Plantar pedis fat pads 2.92 1.32–6.44 0.008 
Face 0.78 0.34–1.82 0.566 
Palm 0.59 0.26–1.34 0.210 
Thigh 1.58 0.66–3.76 0.306 
Gluteal region 1.25 0.54–2.88 0.601 
CIconfidence interval; ORodds ratio; PAIplasminogen activator inhibitor  
 
 
 
